VANCOUVER, Feb. 13 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in advancing novel, targeted therapeutic proteins, today announced that data from the completed Phase 1 clinical study testing PRX302 in patients with locally recurrent prostate cancer following radiation failure will be presented at the American Society of Clinical Oncology (“ASCO”) Genitourinary Cancer Symposium in San Francisco, California.
